Most had received a clozapine trial at some point ( n = 32/36). A minority were currently receiving clozapine ( n = 14/36). They had marked clinical and functional impairment. Tertiary service treatment recommendations are described.įindings: Thirty-six of 48 individuals had TR. Characteristics of clozapine and ECT trials were documented. A detailed casenote review was conducted to examine whether clozapine and/or ECT had ever been prescribed. Methods: All TRSP clients who met the criteria for treatment resistance (TR) were included. Objectives: To (i) describe clinical characteristics of individuals with treatment-resistant psychosis and to detail the proportion who had received a trial of clozapine or ECT at any point during their illness course (ii) describe the characteristics of the treatment trials in both those currently on clozapine and those previously on clozapine (iii) document reasons in relevant individuals why clozapine had never been used. Setting: Statewide public health tertiary referral service, the Tertiary Referral Service for Psychosis (TRSP), NSW, Australia. Identification of clozapine and/or ECT use in real-world practice enables understanding of the extent to which this evidence-base is implemented. ECT has also been reported to improve symptom profiles.
0 kommentar(er)
